HC Wainwright Issues Positive Estimate for AUTL Earnings

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) – Equities research analysts at HC Wainwright increased their Q2 2026 earnings estimates for Autolus Therapeutics in a report issued on Thursday, May 14th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.31) per share for the quarter, up from their prior estimate of ($0.34). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Autolus Therapeutics’ Q3 2026 earnings at ($0.27) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($1.08) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.54) EPS and FY2030 earnings at ($0.20) EPS.

A number of other analysts have also recently commented on the stock. Jefferies Financial Group raised shares of Autolus Therapeutics to a “strong-buy” rating in a report on Monday, April 20th. Zacks Research upgraded shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, March 13th. Mizuho dropped their price target on shares of Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Tuesday, March 31st. Weiss Ratings lowered shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. Finally, Truist Financial upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Autolus Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $8.75.

Autolus Therapeutics Trading Up 10.4%

Shares of AUTL stock opened at $1.80 on Tuesday. Autolus Therapeutics has a 12 month low of $1.18 and a 12 month high of $2.70. The stock has a market cap of $479.05 million, a P/E ratio of -1.65 and a beta of 1.93. The company has a 50 day simple moving average of $1.49 and a two-hundred day simple moving average of $1.52.

Autolus Therapeutics (NASDAQ:AUTL) last announced its earnings results on Friday, May 15th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.02. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. The business had revenue of $26.22 million during the quarter, compared to analysts’ expectations of $26.27 million.

Hedge Funds Weigh In On Autolus Therapeutics

Several institutional investors have recently bought and sold shares of the business. Waverly Advisors LLC bought a new position in Autolus Therapeutics during the first quarter valued at $37,000. Cetera Investment Advisers lifted its position in Autolus Therapeutics by 2.7% during the first quarter. Cetera Investment Advisers now owns 1,129,074 shares of the company’s stock valued at $1,558,000 after purchasing an additional 29,324 shares during the last quarter. R Squared Ltd lifted its position in Autolus Therapeutics by 48.4% during the first quarter. R Squared Ltd now owns 39,575 shares of the company’s stock valued at $55,000 after purchasing an additional 12,915 shares during the last quarter. SmartHarvest Portfolios LLC lifted its position in Autolus Therapeutics by 177.0% during the first quarter. SmartHarvest Portfolios LLC now owns 59,185 shares of the company’s stock valued at $82,000 after purchasing an additional 37,820 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its position in Autolus Therapeutics by 334.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 123,279 shares of the company’s stock valued at $245,000 after purchasing an additional 94,873 shares during the last quarter. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.